Status:
COMPLETED
Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Central Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)
Eligibility Criteria
Inclusion
- Positive history of clinical stroke at least 4 months prior to randomization CPSP--3 months prior to screening
Exclusion
- History of dementia or any other severe cognitive impairment
- Diabetic Peripheral Neuropathy (DPN)
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00313820
Start Date
August 1 2006
End Date
September 1 2008
Last Update
February 9 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia, 2010
2
Pfizer Investigational Site
East Gosford, New South Wales, Australia, 2250
3
Pfizer Investigational Site
St Leonards, New South Wales, Australia, 2065
4
Pfizer Investigational Site
Warrawong, New South Wales, Australia, 2502